18-2-2021

Lu177 is better than cabazitaxel in patients with metastatic castration-resistant prostate cancer.

An unblinded, randomized phase 2 trial at 11 centers in Australia.

the researchers recruited men with metastatic castration-resistant prostate cancer for whom cabazitaxel was considered the next appropriate standard treatment.

Read more about 

Lu-PSMA-617

lu 177 ca - Isotopia